In Brief: Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Perrigo: Receives FDA go-ahead to manufacture clemastine fumarate tablets 1.34 mg with the agency's approval of an ANDA, the company announced Dec. 5. Perrigo has been selling a store-brand version of Sandoz' Tavist-1 antihistamine with ingredient obtained from an outside supplier. Perrigo also sells a store-brand equivalent of Tavist-D with clemastine fumarate 1.34 mg and phenylpropanolamine hydrochloride 75 mg, extended release, under a licensing agreement with Sandoz ("The Tan Sheet" Sept. 19, 1994, p. 4)...